Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy : Results of 2 Randomized Phase 3 Studies by R.P. Singh et al.
Nepafenac 0.3% after Cataract Surgery in
Patients with Diabetic Retinopathy
Results of 2 Randomized Phase 3 Studies
Rishi P. Singh, MD,1 Robert Lehmann, MD,2 Joseph Martel, MD,3 Kevin Jong, MD,4 Ayala Pollack, MD,5
Alexis Tsorbatzoglou, MD, PhD,6 Giovanni Staurenghi, MD,7 Guadalupe Cervantes-Coste Cervantes, MD,8
Louis Alpern, MD,9 Satish Modi, MD,10 Liza Svoboda, MS,11 Adeniyi Adewale, PhD,12 Glenn J. Jaffe, MD13
Purpose: To demonstrate the efﬁcacy and safety of once-daily nepafenac 0.3% ophthalmic suspension
versus vehicle, based on clinical outcomes, after cataract surgery in patients with diabetes.
Design: Two prospective, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies.
Participants: Total, 615 patients in study 1 and 605 patients in study 2.
Methods: Patients were randomized (1:1) to topical nepafenac 0.3% or vehicle once-daily starting the day
before surgery and continuing for 90 days thereafter.
Main Outcome Measures: Key efﬁcacy variables were: patients (%) in whom macular edema (ME) devel-
oped (30% increase from preoperative baseline central subﬁeld macular thickness) within 90 days after cataract
surgery and the patients (%) with a best-corrected visual acuity (BCVA) improvement of 15 letters from pre-
operative baseline through day 14 maintained through day 90. Secondary end points included: patients (%) with a
BCVA improvement of 15 letters from preoperative baseline through days 90 and 60 and safety over 3 months.
Results: A signiﬁcantly lower percentage of patients demonstrated ME within 90 days after surgery with
nepafenac 0.3% versus vehicle (study 1: 2.3% vs. 17.3%; P< 0.001; study 2: 5.9% vs. 14.3%; P ¼ 0.001; pooled:
4.1% vs. 15.9%; P< 0.001). The percentage of patients achieving a15-letter improvement from baseline through
day 14 maintained through day 90 with nepafenac 0.3% versus vehicle was 61.7% versus 43.0% (P < 0.001) in
study 1, 48.8% versus 50.5% (P¼ 0.671) in study 2, and 55.4% versus 46.7% (P¼ 0.003) in the pooled analysis. A
greater percentage of patients treated with nepafenac 0.3% versus vehicle in study 1 and similar percentage in
study 2 had a BCVA improvement of15 letters from preoperative baseline through day 90 (77.2% vs. 67.7% [P¼
0.009] and 65.4% vs. 65.9% [P ¼ 0.888]) and through day 60 (76.2% vs. 64.7% [P ¼ 0.002] and 68.9% vs. 62.1%
[P ¼ 0.092]). No unanticipated adverse events were observed.
Conclusions: These studies demonstrated the clinical beneﬁts of nepafenac 0.3% over vehicle in reducing
the risk of postoperative ME, with the integrated analysis showing improved BCVA after cataract surgery in
patients with diabetic retinopathy, with no unanticipated safety events. Ophthalmology 2017;124:776-785 ª 2017
by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.
Cataract is the leading cause of blindness, affecting 47.8%
of patients worldwide.1 Patients with diabetes are at an
increased risk of developing cataract compared with those
without diabetes, and the rising global prevalence of
diabetes further increases the risk for cataract
development.2,3 Macular edema (ME) is a common cause
of poor visual outcome after uneventful cataract surgery by
phacoemulsiﬁcation.4e6 Approximately 30% of patients
may experience some magnitude of postoperative ME,
although many cases are not associated with impaired
vision.7 Although ME associated with visual acuity (VA)
loss after uneventful cataract surgery has been reported in
up to 2% of patients,4,8 the incidence may be as high as
20% when cataract extraction is complicated by posterior
capsule rupture with vitreous loss or severe iris trauma.4,6
Cataract development occurs at a higher rate and at an
earlier age in patients who have diabetes compared with
those who do not have diabetes.9,10 In addition, macular
changes are more likely to occur after cataract surgery in
patients with diabetes, especially in those with pre-existing
retinopathies, compared with those without diabetes.3
Over the years, optical coherence tomography (OCT) has
emerged as a reliable tool to diagnose and quantitatively
follow changes in retinal pathology.11 Optical coherence
tomography better detects morphologic changes at an
early stage.12 Recent studies using OCT have reported
higher rates of ME after cataract surgery in patients with
diabetes with or without retinopathy (18%e28.6%) than in
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those without diabetes (1%e5.5%).3,13e17 Topical nonste-
roidal anti-inﬂammatory drugs (NSAIDs) are beneﬁcial for
treating ME after cataract surgery.18,19 Nonsteroidal anti-
inﬂammatory drugs block cyclooxygenase enzymes
responsible for prostaglandin production.18,19 Very few
prospective studies have evaluated the role of NSAIDs to
reduce the risk of ME and to improve VA outcomes after
cataract surgery in eyes with diabetic retinopathy.
Nepafenac (Alcon Research, Ltd., Fort Worth, TX), an
NSAID, rapidly permeates into the cornea and sclera and is
converted to its active metabolite, amfenac, primarily in the
retinaechoroid and the iriseciliary body.20,21 Amfenac is a
potent inhibitor of constitutive (cyclooxygenase-1) and
inducible (cyclooxygenase-2) cyclooxygenases that catalyze
the formation of proinﬂammatory prostaglandins.22 Both
nepafenac and amfenac block the inﬂammation-mediated
breakdown of the blooderetinal barrier that contributes to
plasma extravasation and edema.22 Nonclinical and clinical
studies have shown that nepafenac and amfenac reach
the posterior segment of the eye after topical
administration.21,23e26
Nepafenac 0.1% ophthalmic suspension, dosed 3 times
daily, is approved in Europe to reduce the risk of post-
operative ME associated with cataract surgery in adult pa-
tients with diabetes, based on 2 randomized, controlled, phase
3 trials.23,24 In both trials, nepafenac 0.1% signiﬁcantly
reduced the incidence of ME compared with vehicle (study 1:
3.2% vs. 16.7%; P < 0.001; study 2: 5% vs. 17.5%; P ¼
0.012).23,24 Furthermore, a higher percentage of patients in
the nepafenac group compared with the vehicle group had
improvements of15 Early Treatment Diabetic Retinopathy
Study (ETDRS) letters from postoperative baseline through
day 90 (Alcon data on ﬁle). Nepafenac 0.1% showed clini-
cally relevant advantages compared with vehicle to prevent
ME and to improve and maintain VA after cataract surgery in
patients with diabetes (Alcon data on ﬁle). The hypothesis of
the present studies was that 0.3% nepafenac formulation may
achieve these aforementioned beneﬁts with less frequent
dosing. Thus, in 2 similarly designed randomized studies, the
efﬁcacy and safety of nepafenac 0.3% administered once-
daily was assessed to reduce ME and to enhance VA after
cataract surgery in eyes of patients with diabetes and non-
proliferative diabetic retinopathy (NPDR).
Methods
Study Design
Both studies were prospective, randomized, multicenter, vehicle-
controlled, double-masked, parallel-group, phase 3 clinical trials.
Study 1 was conducted at 66 centers in the United States, Latin
America, and the Caribbean between March 2013 and May 2015.
Study 2 was conducted at 73 centers across the United States,
Europe, the Middle East, Africa, Latin America, Caribbean, and the
AsiaePaciﬁc region between June 2013 and May 2015.
The studies consisted of 9 visits as follows: a screening and
randomization visit (performed within 2 days to 4 weeks before the
surgery visit), the cataract surgery visit (day 0), and 6 postoperative
follow-up visits (days 1, 7, 14, 30, 60, and 90 or early exit; Fig 1,
available at www.aaojournal.org). Patients in whom ME was not
resolved by day 90 were considered to be treatment failures;
these patients were followed up until day 120.
In both the studies, all patients, investigators, and the study-
related personnel were masked to the treatment assignment. The
study was conducted in accordance with the Good Clinical Practice
and the tenets of the Declaration of Helsinki. The study protocol
was reviewed and approved by an independent ethics committee or
an institutional review board for each contributing center. All pa-
tients provided written informed consent before entering the study.
The studies are registered with clinicaltrials.gov (identiﬁers,
NCT01853072 [study 1] and NCT01872611 [study 2]).
Patients
Both studies included patients 18 years of age or older with dia-
betes (types 1 or 2) and NPDR who required cataract extraction by
phacoemulsiﬁcation with planned posterior chamber intraocular
lens (IOL) implantation, who had a best-corrected VA (BCVA) of
73 ETDRS letters or fewer (<20/63 Snellen equivalent) in the
study eye at preoperative screening, and who had an expectation of
improvement in BCVA after surgery, in the opinion of the
investigator.
Patients with pre existing ME in the study eye as determined by
spectral-domain (SD) OCT and conﬁrmed by the reading center
(central subﬁeld macular thickness [CSMT], 320 mm [Spectralis;
Heidelberg, Germany] or 300 mm [Cirrus; Zeiss, Germany]) or
who had a history of retinal detachment, ischemic maculopathy,
central or branch retinal vein occlusion, central or branch retinal
artery occlusion, exudative age-related macular degeneration, or
chronic or recurrent inﬂammatory eye disease were excluded.
Additional exclusion criteria were use of intraocular or periocular
corticosteroids or antievascular endothelial growth factor therapy
within 6 months of surgery, systemic or topical ocular corticoste-
roids within 14 days of surgery, topical or systemic NSAIDs
(except an allowed daily dose of 325 mg of aspirin) within 7 days
of surgery, topical ophthalmic prostaglandins within 4 days of
surgery, or topical ocular corticosteroids or NSAIDs 1 day before
surgery. Patients allergic or hypersensitive to NSAIDs, cortico-
steroids, or any component of the investigational product also were
excluded from the study. Detailed exclusion criteria are provided in
Appendix 1 (available at www.aaojournal.org).
Treatment
Enrolled patients were randomized (1:1) to receive nepafenac 0.3%
or vehicle once-daily in the study eye beginning 1 day before
cataract surgery (day 1). Patients were randomized in a 1:1
manner to receive treatment with nepafenac 0.3% and control
vehicle, respectively. Randomization was stratiﬁed by retinopathy
severity (mild vs. moderate or severe) as deﬁned by the Interna-
tional Clinical Diabetic Retinopathy Scale. Both the test articles
(nepafenac 0.3% and vehicle) were provided in identical vials.
Dosing continued on the day of surgery (day 0) and for 90 days
after surgery. On the day of the surgery (day 0), patients received
an additional dose of assigned treatment 30 to 120 minutes before
the surgery. All patients received prednisolone acetate (Omnipred;
Alcon Laboratories Inc., Fort Worth, TX) [prednisolone acetate
ophthalmic suspension] or similar alternate eye drops) in the
operative eye 4 times daily for the ﬁrst 2 weeks after surgery fol-
lowed by twice-daily for the subsequent 2 weeks after surgery.
This topical corticosteroid dosing regimen could be modiﬁed based
on the investigator’s judgment.
Study Objectives
The objective of both the studies was to determine the efﬁcacy and
safety of once-daily nepafenac 0.3% ophthalmic suspension versus
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vehicle based on clinical outcomes after cataract surgery in patients
with diabetes. The primary and secondary end points were as
follows: (1) the percentage of patients who demonstrated ME
(30% increase from the preoperative baseline in CSMT) within
90 days after cataract surgery (primary end point for the European
Medicines Agency Committee for Medicinal Products for Human
Use [EMA CHMP] and secondary end point for the United States
Food and Drug Administration [FDA]); (2) the percentage of pa-
tients with a BCVA improvement of 15 letters from preoperative
baseline through day 14 and maintained through day 90 (primary
end point for the United States FDA and secondary end point for
the EMA CHMP); (3) the percentage of patients with a BCVA loss
of >5 and >10 letters from day 7 to any visit and safety over 90
days; and (4) the percentage of patients with a BCVA improvement
of 15 letters from preoperative baseline through day 90 and day
60. The key supportive end points included mean changes in
BCVA and CSMT from preoperative baseline to each post-
operative visit. Given the identical nature of the protocols, pooled
analyses were conducted to verify the study ﬁndings further.
Efﬁcacy Assessments
The efﬁcacy variables included measurements of BCVA, devel-
opment of ME, macular thickness and volume, and the incidence of
treatment failure. Macular edema was deﬁned as a 30% increase
in CSMT from the preoperative baseline measurement. Macular
thickness and volume were measured using SD OCT (Spectralis or
Cirrus) at each investigational center. Optical coherence tomogra-
phy was assessed on scans obtained from both eyes at screening
and day 90 (or day 120, if applicable, or early exit) and from the
study eye on days 7, 14, 30, and 60. The OCT scans were analyzed
in a masked fashion at the Duke Reading Center (Duke University,
Durham, NC) and included the use of standard segmentation
methods. Thickness results were reported for the foveal center
point, the foveal central 1-mm subﬁeld thickness, and the inner and
outer rings, each of which were divided into 4 quadrants (temporal,
superior, nasal, and inferior). The total macular volume was also
reported.
Fundus photographs were obtained at the screening visit and
were submitted to the reading center for grading of retinopathy
severity (no apparent retinopathy, mild NPDR, moderate NPDR,
severe NPDR, and proliferative diabetic retinopathy) as deﬁned by
the International Clinical Diabetic Retinopathy Scale before
randomization. The BCVA was assessed by a certiﬁed VA tech-
nician and refractionist using a standard ETDRS chart at a distance
of 4 m (and 1 m as necessary) in both eyes at baseline and at day 90
(or day 120, if applicable, or early exit) as well as in the study eye
on days 1, 7, 14, 30, and 60. The BCVA was calculated at 4 m as
the number of letters read correctly þ30, whereas BCVA was
calculated at 1 m as the number of letters read correctly. Regardless
of distance, if no letters were read correctly, the BCVA was re-
ported as 0 and the patient was to have been tested, in respective
order, for the following levels of acuity: counting ﬁngers, hand
movements, and light perception. The BCVA assessment was
standardized across all investigational centers. Treatment failure
was deﬁned as any eye with a 30% or more increase in CSMT
from the preoperative baseline assessment as measured by SD
OCT.
Safety Assessments
Information on adverse events (AEs) in all patients was collected
from screening and at all visits through day 90 (or day 120, if
applicable, or early exit). In addition to the AE assessments, the
safety of nepafenac 0.3% was assessed by routine ocular
examinations, which included intraocular pressure (IOP) mea-
surements, slit-lamp parameters (inﬂammatory cells, aqueous ﬂare,
corneal edema, bulbar redness, and corneal epithelium integrity),
dilated fundus parameters (peripheral retina, macula, choroid, and
optic nerve), and the extent of exposure.
Statistical Analysis
A sample size of 590 patients was planned to achieve an evaluable
sample size of 560 patients that was expected to provide approx-
imately 90% power to detect a 14% difference between the nepa-
fenac 0.3% and vehicle groups for the BCVA end point (assuming
45% in the vehicle group) and a more than 99% power to detect at
least a 13% difference for the incidence of ME (assuming 18% in
the vehicle group).
The efﬁcacy analyses were performed using the full analysis set
(FAS), which included all randomized patients who completed
implant surgery and had at least 1 on-therapy postoperative visit.
The BCVA end point (primary end point for the United States
FDA and secondary end point for the EMA CHMP) was based on
a binary outcome (positive or negative). A positive outcome
required an improvement from the preoperative baseline BCVA of
15 letters at all 4 time points (days 14, 30, 60, and 90); any other
outcome was considered negative. A logistic regression model for
treatment and retinopathy severity was performed to assess the
treatment group difference in BCVA. The primary inference was
based on the odds ratio of a positive outcome. An estimate of the
odds ratio, the associated 95% conﬁdence interval (CI), and P
value were provided, along with the difference in proportions and
associated CIs. A similar model was used to analyze the per-
centage of patients who demonstrated ME within 90 days (primary
end point for EMA CHMP and secondary end point for United
States FDA) and the other secondary efﬁcacy end points associated
with changes in BCVA. The analyses of the supportive end points
were descriptive. The primary and secondary analyses were
repeated using the per-protocol (PP) analysis set, which included
all patients in the FAS who had no major protocol violations, to
investigate the sensitivity of the results to major protocol
violations.
A gatekeeping strategy was used to ensure overall control of the
type I error rate at a 5% level of signiﬁcance (2 sided). The sec-
ondary efﬁcacy hypotheses were relevant only if the primary ef-
ﬁcacy null hypothesis was ﬁrst rejected. The order of hypothesis
testing was region speciﬁc. After the rejection of the primary null
hypothesis, each secondary hypothesis was tested following the
order of the hypotheses as listed for each region. For the European
Union, the order of the hypotheses was consistent with the listing
under study objectives. For the United States, the end point of
maintained improvement in BCVA was considered as the primary
end point and the ME end point was considered as the ﬁrst sec-
ondary end point. The data presented in the manuscript follow the
testing order of the European Union.
A pooled analysis of the 2 studies also was performed to gain
better precision in estimating the treatment effects in patients with
NPDR and to assess the consistency of the ﬁndings of the indi-
vidual studies. The efﬁcacy outcomes of pooled analysis were to be
considered as only supportive of the individual study ﬁndings, and
thus no formal multiplicity adjustment were used.
The safety analysis set included all patients who were exposed
or were deemed exposed (i.e., discontinued the study before sur-
gery, but either returned an opened bottle of the study drug or
failed to return the study drug) to treatment. Descriptive statistics
were used to summarize all safety parameters by visit and treatment
group.
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Results
Patient Demographics and Baseline
Characteristics
In study 1, 615 patients (615 eyes) were randomized 1:1 to
receive nepafenac 0.3% (n ¼ 308) or vehicle (n ¼ 307). Of these
615 patients, 12 (7 in the nepafenac 0.3% group and 5 in the
vehicle group) did not receive treatment and were excluded from
the analysis sets. All 603 patients who received treatment were
included in the safety analysis set; 598 were included in the FAS
and 557 were included in the PP analysis set. Overall, 12
patients in the nepafenac 0.3% group and 21 patients in the
vehicle group discontinued the study. The reasons for study
discontinuation are provided in Figure 2A (available at
www.aaojournal.org).
In study 2, 605 patients (605 eyes) were randomized 1:1 to
receive nepafenac 0.3% (n ¼ 301) or vehicle (n ¼ 304). Of the 605
patients, 17 (8 in the nepafenac 0.3% group and 9 in the vehicle
group) did not receive treatment and were excluded from the
analysis. All 588 patients who received treatment were included in
the safety analysis set; 582 were included in the FAS and 552 were
included in the PP analysis set. Overall, 24 patients in the nepa-
fenac 0.3% group and 12 patients in the vehicle group discontinued
the study. The reasons for study discontinuation are provided in
Figure 2B (available at www.aaojournal.org).
Overall in both the studies, the patient demographics and
baseline characteristics were well balanced, with no clinically
relevant between-group differences (Table 1). Most patients were
65 years of age or older, female, and white.
Efﬁcacy
For simplicity of reporting, the end points reported below are
presented in the order of nominal statistical signiﬁcance. For
multiplicity considerations, please refer to the description in
methods under statistical analysis.
Macular Edema
In both the studies, a signiﬁcantly lower percentage of eyes in the
nepafenac 0.3% versus the vehicle group developed ME within 90
days after cataract surgery (study 1: 2.3% vs. 17.3%; P < 0.001;
study 2: 5.9% vs. 14.3%; P ¼ 0.001; Fig 3). The results of the
analysis using the PP analysis set were consistent with those
from the primary analysis (study 1: 2.2% vs. 16.2%; P < 0.001;
study 2: 4.4% vs. 13.0%; P < 0.001; Table 2, available at
www.aaojournal.org).
Best-Corrected Visual Acuity
BCVA Improvement of ‡15 Letters from Preoperative Baseline
to Day 14 and Maintained through Day 90. In study 1, a
signiﬁcantly higher percentage of eyes in the nepafenac 0.3%
versus the vehicle group (61.7% vs. 43.0%; P < 0.001) achieved a
clinically relevant improvement of 15 letters from preoperative
baseline through day 14, that was maintained through day 90 (Fig
4). In study 2, similar percentages of eyes in both the treatment
groups achieved this end point (nepafenac 0.3%, 48.8%; vehicle,
50.5%; P ¼ 0.671; Fig 4). The results of the PP analysis set
were consistent with those from the primary analysis (study 1:
56.6% vs. 35.6%; P < 0.001; study 2: 46.5% vs. 43.0%; P ¼
0.400; Table 2, available at www.aaojournal.org).
Percentage of Eyes with a BCVA Loss of >5 and >10 Letters
from Day 7 to Any visit. A lower percentage of eyes receiving
nepafenac 0.3% in study 1 compared with those receiving vehicle
lost >5 letters from day 7 to any visit (study 1: 15.4% vs. 27.3%; P
< 0.001; Fig 5A, available at www.aaojournal.org). This effect
was not observed in study 2, where similar percentages of eyes
had BCVA loss of >5 letters in either group (18.7% vs. 16.7%;
P ¼ 0.540). Fewer eyes in the nepafenac 0.3% group than in the
vehicle group had a >10-letter loss in BCVA from day 7 to any
visit in study 1 (study 1: 9.1% vs. 15.3%; P ¼ 0.02); however,
the percentages of eyes were similar between treatment groups in
study 2 (10.7% vs. 8.9%; P ¼ 0.458; Fig 5B, available at
www.aaojournal.org).
Table 1. Patient Demographics and Baseline Characteristics
Characteristics
Study 1 Study 2 Pooled
Nepafenac
(n ¼ 289)
Vehicle
(n¼ 300)
Nepafenac
(n ¼ 289)
Vehicle
(n ¼ 293)
Nepafenac
(n ¼ 587)
Vehicle
(n ¼ 593)
Mean age (SD), years 66.8 (8.5) 66.8 (8.3) 67.7 (8.5) 68.1 (8.4) 67.2 (8.5) 67.4 (8.3)
18e64 100 (33.6) 110 (36.7) 101 (34.9) 84 (28.7) 201 (34.2) 194 (32.7)
65 198 (66.4) 190 (63.3) 188 (65.1) 209 (71.3) 386 (65.8) 399 (67.3)
Female gender, n (%) 158 (53.0) 166 (55.3) 149 (51.6) 149 (50.9) 307 (52.3) 315 (53.1)
Race, n (%)
White 220 (73.8) 231 (77.0) 174 (60.2) 169 (57.7) 394 (67.1) 400 (67.5)
Black 50 (16.8) 44 (14.7) 13 (4.5) 11 (3.8) 63 (10.7) 55 (9.3)
Alaska native 0 0 1 (0.3) 0 1 (0.2) 0
Asian 5 (1.7) 5 (1.7) 26 (9.0) 34 (11.6) 31 (5.3) 39 (6.6)
Native Hawaiian/Paciﬁc Islander 0 1 (0.3) 0 1 (0.3) 0 2 (0.3)
Multiracial 0 0 2 (0.7) 0 2 (03) 0
Other 23 (7.7) 19 (6.3) 73 (25.3) 78 (26.6) 96 (16.4) 97 (16.4)
Mean CSMT (SD), mm 245.4 (24.2) 247.6 (25.0) 246 (25.0) 247.8 (23.4) 245.7 (24.6) 247.7 (24.2)
Mean BCVA (SD), letters 62.0 (12.1) 63.0 (11.0) 59.6 (14.0) 59.8 (12.4) 60.8 (13.1) 61.4 (11.8)
Retinopathy severity, n (%)
Mild 40 (13.4) 44 (14.7) 29 (10.0) 33 (11.3) 69 (11.8) 77 (13.0)
Moderate 255 (85.6) 253 (84.3) 260 (90.0) 257 (87.7) 515 (87.7) 510 (86.0)
Severe 3 (1.0) 3 (1.0) 0 (0) 3 (1.0) 3 (0.5) 6 (1.0)
BCVA ¼ best-corrected visual acuity; CSMT ¼ central subﬁeld macular thickness; SD ¼ standard deviation.
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BCVA Improvement of ‡15 Letters from Preoperative
Baseline to Day 60 and to Day 90. In study 1, a signiﬁcant
improvement of 15 letters was observed with nepafenac 0.3%
versus vehicle from preoperative baseline through day 90 (77.2% vs.
67.7%; P¼ 0.009) and day 60 (76.2% vs. 64.7%; P¼ 0.002; Fig 6A
and B). In study 2, the between-group difference was not signiﬁcant;
numerical difference in favor of nepafenac 0.3% was observed for a
BCVA improvement of 15 letters from preoperative baseline
through day 60 (68.9% vs. 62.1%;P¼ 0.092), whereas the outcomes
were similar for a BCVA improvement of 15 letters from preop-
erative baseline through day 90 (65.4% vs. 65.9%; P ¼ 0.888;
Fig 6A and B).
Mean Change in BCVA and CSMT from Preoperative
Baseline to Each Visit. In both the studies, an overall BCVA
improvement was observed based on the mean change in BCVA
from baseline to each postoperative study visit. The improvement
was higher in the nepafenac 0.3% group than in the vehicle group
at all postoperative visits from days 7 to 90 in both studies (P <
0.05), except on the day 7 visit in study 2 (P ¼ 0.088; Fig 7). In
both studies, the increase in CSMT from preoperative baseline
was smaller in the nepafenac 0.3% group than in the vehicle
group at all postoperative visits from days 7 through 90
(P < 0.05 at all visits in both studies; Fig 8).
Pooled Analysis
A notable difference was observed with nepafenac 0.3% versus
vehicle in the incidence of ME (4.1% vs. 15.9%; P < 0.001; Fig 3)
and in BCVA improvement of 15 letters from preoperative
baseline through day 14 and maintained through day 90 (55.4%
vs. 46.7%; P ¼ 0.003). A lower proportion of eyes in the
nepafenac 0.3% group showed a BCVA loss of >5 letters
(17.0% vs. 22.1%; P ¼ 0.029) or >10 letters (9.9% vs. 12.1%;
P ¼ 0.211) from day 7 compared with the vehicle group
(Fig 5A and B, available at www.aaojournal.org). More eyes in
the nepafenac 0.3% group versus the vehicle group had a BCVA
improvement of 15 letters from preoperative baseline through
day 60 (72.6% vs. 63.4%; P < 0.001) and day 90 (71.4% vs.
66.8%; P ¼ 0.088; Fig 6A and B).
Safety
Overall in study 1, 108 patients (35.9%) in the nepafenac 0.3%
group and 125 patients (41.4%) in the vehicle group experienced
at least 1 treatment-emergent AE (TEAE). Of these, 8 patients
(2.7%) in the nepafenac 0.3% group and 7 patients (2.3%) in the
vehicle group reported treatment-related TEAEs. In addition, 4
patients experienced treatment-related AEs during the posttreat-
ment period, which included keratitis (1 patient in the nepafenac
0.3% group and 2 patients in the vehicle group) and punctate
keratitis (1 patient in the vehicle group). One patient in the vehicle
group died during the treatment-period because of a serious TEAE
(sepsis). In addition, 1 patient in the nepafenac 0.3% group and 3
patients in the vehicle group died because of serious TEAEs
during the posttreatment period. Thirteen (4.3%) patients in each
treatment group experienced at least 1 nonfatal serious TEAE.
Four patients (1.3%) in the vehicle group discontinued the study
because of a TEAE; there was no discontinuation due to TEAE in
nepafenac 0.3% group (Table 3).
In study 2, overall 102 patients (34.8%) in the nepafenac 0.3%
group and 136 patients (46.1%) in the vehicle group experienced at
least 1 TEAE. Of these, 6 patients (2.0%) in the nepafenac 0.3%
group and 8 patients (2.7%) in the vehicle group reported
treatment-related TEAEs. In addition, 3 patients experienced
treatment-related TEAEs during the posttreatment period, which
included punctate keratitis (1 patient in the vehicle group), retinal
detachment (1 patient in the nepafenac 0.3% group), and diabetic
retinal edema (1 patient in the vehicle group). One patient in the
vehicle group died during the treatment-period because of a serious
TEAE (cardiac failure). One patient who never received the study
treatment died because of a serious AE during the pretreatment
period. No deaths were reported in the nepafenac 0.3% group.
Fourteen patients (4.8%) in the nepafenac 0.3% group and 13
patients (4.4%) in the vehicle group experienced at least 1 nonfatal
serious TEAE. One patient in the nepafenac 0.3% group and 1
patient in the vehicle group discontinued the study because of a
TEAE (Table 3).
Figure 3. Bar graph showing the incidence of macular edema within 90 days
after cataract surgery in patients treated with nepafenac 0.3% and vehicle
and the associated odds ratio (OR; 95% conﬁdence interval [CI]) in each
study and in the pooled analysis (full analysis set). P value for pooled analysis
is for descriptive purposes only. *OR, 0.1 (95% CI, 0.1e0.3). **OR, 0.4
(95% CI, 0.2e0.7). yOR, 0.2 (95% CI, 0.1e0.4). SE ¼ standard error.
Figure 4. Bar graph showing the percentage of patients with best-corrected
visual acuity improvement of 15 letters or more from preoperative baseline
through day 14 and maintained through day 90 in patients treated with
nepafenac 0.3% and vehicle and the associated odds ratio (OR; 95%
conﬁdence interval [CI]) in each study and in the pooled analysis (full
analysis set). P value for pooled analysis is for descriptive purposes only.
*OR, 2.1 (95% CI, 1.5e3.0). **OR, 0.9 (95% CI, 0.7e1.3). yOR, 1.4
(95% CI, 1.1e1.8). SE ¼ standard error.
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In both the studies, none of the deaths were considered by the
investigator to be related to the study treatment; none of the serious
TEAEs or TEAEs that led to study discontinuation were considered
by the investigator to be treatment-related. In both studies, a review
of ocular examination results (IOP, slit-lamp biomicroscopy, and
dilated fundus examination) revealed no meaningful treatment
differences between the nepafenac 0.3% and vehicle groups.
Discussion
The 2 randomized, vehicle-controlled phase 3 studies
demonstrated that nepafenac 0.3%, when given once-daily
beginning 1 day before surgery and continued for 90 days,
was superior to vehicle in reducing the risk of ME after
cataract surgery in patients with diabetes. In study 1, clini-
cally relevant differences between nepafenac 0.3% and
vehicle were observed for all the BCVA end points, whereas
in study 2, the outcomes were similar between the nepafenac
0.3% and vehicle groups. The BCVA outcomes in the pooled
analysis were similar to the results observed in study 1 (Fig 9,
available at www.aaojournal.org).
In the current studies, the primary analysis was conducted
on the FAS. The BCVA end point was not met using the FAS
in study 2, which remains a potential limitation of these
ﬁndings. However, results based on the PP analysis were in
favor of nepafenac 0.3% for several of the BCVA end points.
Notable differences in favor of nepafenac 0.3% (at the nom-
inal 5% signiﬁcance level) were observed for >5-letter and
>10-letter loss from day 7 end points and for the 15-letter or
more gain from preoperative baseline to the day 60 end point
(Table 2, available at www.aaojournal.org). Numerous post
hoc subgroup analyses were conducted in study 2 to
understand the reasons for the similar BCVA outcomes
between treatments. These included subgroup analyses by
the geographic location of the participating patients (by
region, country, and investigational center), by patient
demographics and baseline characteristics (e.g., age, gender,
race, retinopathy severity, and VA), and by factors related
to the medical history or concomitant medications (type and
duration of diabetes, type of concomitant steroid, and
others; Alcon data on ﬁle). These additional analyses did
not reveal any single factor that could explain the similar
Figure 6. Bar graph showing the best-corrected visual acuity improvement of 15 letters or more from preoperative baseline to (A) day 60 and (B) day 90 in
patients treated with nepafenac 0.3% and vehicle and the associated odds ratio (OR; 95% conﬁdence interval [CI]) in each study and in the pooled analysis
(full analysis set). P value for pooled analysis is for descriptive purposes only. A, *OR, 1.8 (95% CI, 1.2e2.5). **OR, 1.3 (95% CI, 1.0e1.9). yOR, 1.5 (95%
CI, 1.2e2.0). B, *OR, 1.6 (95% CI, 1.1e2.3). **OR, 1.0 (95% CI, 0.7e1.4). yOR, 1.2 (95% CI, 1.0e1.6). SE ¼ standard error.
Figure 7. Graph showing the mean change in best-corrected visual acuity
(BCVA) from preoperative baseline to each visit in patients treated with
nepafenac 0.3% and vehicle in each study and in the pooled analysis (full
analysis set). P value for pooled analysis is for descriptive purposes only.
Pre-op ¼ before surgery.
Figure 8. Graph showing the mean change in central subﬁeld macular
thickness (CSMT) from preoperative baseline to each visit in patients
treated with nepafenac 0.3% and vehicle in each study and in the pooled
analysis (full analysis set). P value for pooled analysis is for descriptive
purposes only. Pre-op ¼ before surgery.
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BCVA outcomes between the nepafenac 0.3% and vehicle
treatment groups, and the results were consistent with the
BCVA results observed in the overall study population.
Given the positive results of both studies with regard to ME
and the BCVA results observed in study 1, which are
consistent with the ﬁndings23,24 reported previously for
Table 3. Treatment-Emergent Adverse Events (Safety Population)
Parameters
Study 1 Study 2
Nepafenac 0.3% (n ¼ 301) Vehicle (n ¼ 302) Nepafenac 0.3% (n ¼ 293) Vehicle (n ¼ 295)
At least 1 TEAE 108 (35.9) 125 (41.4) 102 (34.8) 136 (46.1)
Related to treatment 8 (2.7) 7 (2.3) 6 (2.0) 8 (2.7)
Any serious TEAE 13 (4.3) 14 (4.6) 14 (4.8) 14 (4.7)
Deaths 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.3)
Nonfatal serious TEAE 13 (4.3) 13 (4.3) 14 (4.8) 13 (4.4)
Related to treatment 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinuation because of TEAE 0 (0.0) 4 (1.3) 1 (0.3) 1 (0.3)
Related to treatment 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Most frequent TEAEs*
Intraocular pressure increase 13 (4.3) 12 (4.0) 10 (3.4) 12 (4.1)
Dry eye 5 (1.7) 12 (4.0) 6 (2.0) 9 (3.1)
Corneal edema 2 (0.7) 2 (0.7) 4 (1.4) 12 (4.1)
Eye pain 5 (1.7) 10 (3.3) 1 (0.3) 8 (2.7)
Macular edema 2 (0.7) 5 (1.7) 2 (0.7) 10 (3.4)
Punctate keratitis 8 (2.7) 5 (1.7) 5 (1.7) 8 (2.7)
Foreign body sensation in eyes 3 (1.0) 8 (2.6) 4 (1.4) 2 (0.7)
Headache 3 (1.0) 8 (2.6) 4 (1.4) 6 (2.0)
Nasopharyngitis 4 (1.3) 4 (1.3) 3 (1.0) 7 (2.4)
Vitreous ﬂoaters 2 (0.7) 6 (2.0) 2 (0.7) 1 (0.3)
Eye irritation 3 (1.0) 6 (2.0) 2 (0.7) 1 (0.3)
Conjunctivitis 5 (1.7) 1 (0.3) 0 (0.0) 4 (1.4)
Diarrhea 2 (0.7) 4 (1.3) 0 (0.0) 0 (0.0)
Keratitis 3 (1.0) 3 (1.0) 0 (0.0) 1 (0.3)
Lacrimation increased 1 (0.3) 5 (1.7) 0 (0.0) 1 (0.3)
Nausea 4 (1.3) 1 (0.3) 1 (0.3) 0 (0.0)
Ocular discomfort 1 (0.3) 4 (1.3) 0 (0.0) 0 (0.0)
Urinary tract infection 2 (0.7) 3 (1.0) 2 (0.7) 2 (0.7)
Cardiac failure congestive 0 (0.0) 4 (1.3) 0 (0.0) 1 (0.3)
Hypokalemia 1 (0.3) 3 (1.0) 0 (0.0) 0 (0.0)
Iritis 1 (0.3) 3 (1.0) 0 (0.0) 1 (0.3)
Cellulitis 0 (0.0) 3 (1.0) 1 (0.3) 1 (0.3)
Noncardiac chest pain 0 (0.0) 3 (1.0) 0 (0.0) 0 (0.0)
Sepsis 0 (0.0) 3 (1.0) 0 (0.0) 0 (0.0)
Vision blurred 0 (0.0) 3 (1.0) 0 (0.0) 1 (0.3)
Upper respiratory tract infection 3 (1.0) 0 (0.0) 0 (0.0) 4 (1.4)
Visual acuity reduced 0 (0.0) 3 (1.0) 6 (2.0) 2 (0.7)
Diabetic retinal edema 2 (0.7) 2 (0.7) 1 (0.3) 6 (2.0)
Ocular hypertension 2 (0.7) 0 (0.0) 4 (1.4) 3 (1.0)
Conjunctival hemorrhage 2 (0.7) 4 (1.3) 1 (0.3) 5 (1.7)
Corneal epithelium defect 0 (0.0 0 (0.0) 3 (1.0) 3 (1.0)
Inﬂuenza 1 (0.3) 0 (0.0) 0 (0.0) 6 (2.0)
Corneal disorder 0 (0.0) 0 (0.0) 5 (1.7) 0 (0.0)
Anterior chamber cell 0 (0.0) 1 (0.3) 1 (0.3) 3 (1.0)
Blepharitis 2 (0.7) 0 (0.0) 1 (0.3) 3 (1.0)
Corneal abrasion 0 (0.0) 1 (0.3) 1 (0.3) 3 (1.0)
Eye injury 1 (0.3) 0 (0.0) 3 (1.0) 1 (0.3)
Posterior capsule opaciﬁcation 2 (0.7) 1 (0.3) 1 (0.3) 3 (1.0)
Posterior capsule rupture 0 (0.0) 2 (0.7) 4 (1.4) 0 (0.0)
Bronchitis 2 (0.7) 2 (0.7) 3 (1.0) 0 (0.0)
Cystoid macular edema 1 (0.3) 1 (0.3) 0 (0.0) 3 (1.0)
Sinusitis 0 (0.0) 1 (0.3) 0 (0.0) 3 (1.0)
Uveitis 0 (0.0) 1 (0.3) 0 (0.0) 3 (1.0)
Viral infection 1 (0.3) 1 (0.3) 0 (0.0) 3 (1.0)
Vitreous hemorrhage 0 (0.0) 1 (0.3) 3 (1.0) 0 (0.0)
TEAE ¼ treatment-emergent adverse event.
Data are no. (%).
*Incidence 1% or more of patients in any treatment group in any study.
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nepafenac 0.1%, it is reasonable to assume that the more
likely error is a type II error (false negative) in study 2 than a
type I error (false positive) in study 1 for the BCVA end
points. Furthermore, it is also reasonable to assume that the 2
studies were conducted on similar patient populations.
However, regional differences in medical practices (e.g.,
cataract surgery technique) and compliance also may have
played a role.
In the present studies, MEwas deﬁned as a30% increase
in CSMT from the preoperative baseline. This increase in
CSMT is well above the 10% coefﬁcient of variation asso-
ciated with SD OCT repeat testing variability3 and translates
to an absolute change of at least 60 mm in CSMT.27 Central
subﬁeld macular thickness, instead of center point
thickness, was chosen in the present and previous studies of
nepafenac because it has been shown to have greater
reliability than center point macular thickness.28
Macular edema remains a common cause of suboptimal
vision after cataract surgery. Patients with diabetes have an
increased risk of experiencing postsurgical complications
and associated poor visual outcomes after cataract surgery.3
Thus, it is important to monitor macular changes in patients
with diabetes after cataract surgery. The signs and
symptoms of clinically signiﬁcant ME develop within 4 to
12 weeks after surgery and peak approximately 4 to 6
weeks after surgery.29 Even in this study, most incidences
of ME in the vehicle group occurred on the day 14, day
30, and day 60 visits, and the incidence was the highest
on day 30 (Fig 8). The incidence of ME in the vehicle
group observed in this study is consistent with that
observed in the 2 nepafenac 0.1% studies conducted of
patients with diabetes.23,24 This present study evaluated
patients for occurrence of ME over a 3-month postoperative
period only. Hence, the efﬁcacy of nepafenac 0.3% in pa-
tients with chronic ME (lasting for 6 months) needs to be
assessed in future studies.
Kim et al30 suggest that the use of NSAIDs before
surgery may speed up visual recovery in the ﬁrst several
weeks after cataract surgery; however, the evidence
supporting long-term beneﬁts to prevent vision loss from
ME at 3 months or more is lacking. This study also provides
evidence supporting the beneﬁts of using NSAIDsd
prophylactically beginning 1 day before surgery, on the day
of surgery, and continued for the initial 3-month post-
operative period, in high-risk patients with diabetes.
In both of the studies, relatively few patients experienced
AEs that were considered by the investigator to be treatment
related, and the percentages were similar between the
groups. It is known that increases in IOP can occur during or
after cataract surgery.31,32 None of the TEAEs of IOP in-
crease that occurred in this study were considered treatment
related. The overall safety proﬁle of nepafenac 0.3%, dosed
once-daily beginning the day before surgery and continued
for 90 days thereafter, was comparable with that of nepa-
fenac 0.1% dosed thrice-daily for the same duration in pa-
tients with diabetic retinopathy.
In conclusion, nepafenac 0.3% given once-daily for 90
days after surgery was superior to vehicle in reducing the
risk of postoperative ME associated with cataract surgery in
both the studies and in the pooled analysis, whereas the VA
was improved and maintained in study 1 and in the pooled
analysis. The safety results were consistent with the estab-
lished safety proﬁle of nepafenac, and no new safety con-
cerns were observed.
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Pictures & Perspectives
Profound Macular Ischemia on Optical Coherence
Tomography Angiography in Severe Diabetic Retinopathy
A 24-year-old woman with type I diabetes mellitus with
signiﬁcant macular ischemia in her left eye with a large net of
neovascularization of the disc (Fig 1A). There is profound
retinal capillary nonperfusion contrasting with perfusion of the
neovascularization of the disc demonstrated on a full thickness
66-mm optical coherence tomographyangiography scan
(Fig 1B), using Angiovue software (Optovue, Inc. Fremont,
CA). On horizontal B-scan raster there is signiﬁcant attenuation
of the ellipsoid zone and outer retinal layers (Fig 1C).
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